NCT04537351 - The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

April 27, 2022

Study Completion Date

May 18, 2022

Conditions

Covid19Acute Respiratory Distress Syndrome

Interventions

BIOLOGICAL

CYP-001

The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.

Trial Locations (5)

2145

Westmead Hospital, Westmead

2217

St George Hospital, Kogarah

2747

Nepean Hospital, Kingswood

3011

Footscray Hospital, Footscray

3021

Sunshine Hospital, Saint Albans